SCHEMBL4563643

SCHEMBL4563643

CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(NS(C)(=O)=O)c3)cc2F)n(-c2ccc3ncccc3c2)n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.75
ABL1 P00519 6/20 0.75
BRAF P15056 6/20 0.75
SRC P12931 3/20 0.75
AXL P30530 2/20 0.75
RIPK1 Q13546 2/20 0.75
PLK4 O00444 1/20 0.75
ACOX3 O15254 1/20 0.75
MAP3K7 O43318 1/20 0.75
DYRK3 O43781 1/20 0.75
JAK2 O60674 1/20 0.75
ERN1 O75460 1/20 0.75
RPS6KA4 O75676 1/20 0.75
STK10 O94804 1/20 0.75
MAP4K4 O95819 1/20 0.75
RAF1 P04049 1/20 0.75
NTRK1 P04629 1/20 0.75
LCK P06239 1/20 0.75
FYN P06241 1/20 0.75
CDK1 P06493 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30681100 0.92 MAPK14 (0.82) MAPK14ABL1BRAFSRCAXL
SCHEMBL2029929 0.92 MAPK14 (0.82) MAPK14ABL1BRAFSRCAXL
SCHEMBL2028647 0.91 MAPK14 (0.73) MAPK14ABL1BRAFSRCAXL
Hydrochloric Acid SCHEMBL2025402 0.91 MAPK14 (0.81) MAPK14ABL1BRAFSRCAXL
SCHEMBL5052381 0.91 MAPK14 (0.78) MAPK14ABL1BRAFSRCAXL
SCHEMBL5055148 0.90 MAPK14 (0.62) MAPK14ABL1BRAFSRCAXL
SCHEMBL5062613 0.90 MAPK14 (0.61) MAPK14ABL1BRAFSRCAXL
SCHEMBL5055270 0.90 ABL1 (0.80) MAPK14ABL1BRAFSRCAXL
SCHEMBL2027848 0.90 MAPK14 (0.76) MAPK14ABL1BRAFSRCAXL
SCHEMBL25639078 0.89 BRAF (0.81) MAPK14ABL1BRAFSRCAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed
EP-2073811-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-07-01 EP disclosed
WO-2008046003-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 MAPK14 100/4885ABL1 20/4885BRAF 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.